Digoxin, a drug commonly used to treat heart conditions, was associated with a 72 percent higher rate of death among adults with newly diagnosed systolic heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Cardiovascular Quality and Outcomes.
Digoxin is a drug derived from digitalis, a plant that has been used for more than 200 years to treat heart failure.
"These findings suggest that the use of digoxin should be reevaluated for the treatment of systolic heart failure in contemporary clinical practice" said Alan S. Go, MD, senior author of the study and research scientist at the Kaiser Permanente Division of Research.
The results of this study contrast with the findings of a randomized trial by the Digitalis Investigation Group conducted between 1991 and 1993, which showed that digoxin did not lower mortality among therapy patients with systolic heart failure, or, a malfunction in the way the left ventricle of the heart pumps blood. Following the group's study, professional societies issued clinical guidelines endorsing the use of digoxin for patients with systolic dysfunction.
The current study was conducted among 2,891 adults within Kaiser Permanente in Northern California who had newly diagnosed systolic heart failure between 2006 and 2008 and no prior digoxin use. Eighteen percent of the participants initiated digoxin during the study period.
Researchers followed the patients through December 31, 2010, to evaluate the effectiveness and safety of digoxin therapy. They found that digoxin use was associated with higher mortality but no significant difference in the risk of heart failure hospitalization.
There were a total of 801 deaths (737 off digoxin and 64 on digoxin). After adjustment for potential confounders, digoxin use was associated with a 72 percent higher relative rate of death.
There were 1,723 hospitalizations for heart failure overall (1,596 off digoxin, 127 on digoxin). However, after adjustment for potential confounders, digoxin use was not significantly associated with hospitalization for heart failure.
"Our community-based study population is more likely to represent patients with systolic heart failure in the modern era with regard to pathogenesis and treatment patterns," Dr. Go said. "Therefore, our results may more accurately represent the outcomes expected with digoxin for patients with systolic heart failure in typical present-day practices. As with all medication, treatment, or therapy plans, care decisions should always be made by physicians and their patients working together, with the patient's particular care needs and goals in mind."
Explore further: Study finds common drug increases deaths in atrial fibrillation patients
Medical Xpress on facebook
Related Stories
Study finds common drug increases deaths in atrial fibrillation patients
Nov 27, 2012
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of ...
Digoxin reduces hospital admissions in older patients with chronic heart failure
Mar 12, 2013
Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented today ...
Popular heart drug may be unsafe for some kidney patients
Jun 24, 2010
For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American So ...
New study finds digoxin safe despite recent reports
Apr 16, 2013
A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation (AF), the opposite of results just published by another group in the same journa ...
Ancient heart drug activates body's own protective mechanisms in blood vessels
Jun 14, 2012
An ancient heart drug that's inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.
Recommended for you
Groundbreaking procedure using novel 'paper-clip' style device to treat high blood pressure
4 hours ago
Researchers at the University of Leicester and Glenfield Hospital have successfully used a novel "paper-clip" sized vascular coupling device to tackle resistant high blood pressure.
Increased QRS duration on ECG tied to cardiovascular mortality
23 hours ago
(HealthDay)—Increased QRS duration on electrocardiogram (ECG) is an independent predictor of cardiovascular mortality, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.
Researchers envision switching a heart beat on and off with light
Sep 19, 2013
With a few flicks of a light switch—on-off-on-off—Stanford University's Oscar Abilez is one step closer to changing the lives of millions.
National registry report shows increase in radial stenting, other CV trends
Sep 18, 2013
Cardiologists are increasingly accessing coronary arteries by way of the wrist rather than the groin to insert life-saving stents into patients with blocked arteries, according to the first broad report of the American College ...
UCLA doctors successfully 'vacuum' two-foot blood clot out of patient's heart
Sep 18, 2013
Todd Dunlap, 62, arrived at Ronald Reagan UCLA Medical Center's emergency room on Aug. 8 suffering from shortness of breath, fatigue and extreme cold. When a CT scan revealed a 24-inch clot stretching from his legs into his ...
Different hormone therapy formulations may pose different risks for heart attack and stroke
Sep 18, 2013
Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Digoxin, a drug commonly used to treat heart conditions, was associated with a 72 percent higher rate of death among adults with newly diagnosed systolic heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Cardiovascular Quality and Outcomes.
Digoxin is a drug derived from digitalis, a plant that has been used for more than 200 years to treat heart failure.
"These findings suggest that the use of digoxin should be reevaluated for the treatment of systolic heart failure in contemporary clinical practice" said Alan S. Go, MD, senior author of the study and research scientist at the Kaiser Permanente Division of Research.
The results of this study contrast with the findings of a randomized trial by the Digitalis Investigation Group conducted between 1991 and 1993, which showed that digoxin did not lower mortality among therapy patients with systolic heart failure, or, a malfunction in the way the left ventricle of the heart pumps blood. Following the group's study, professional societies issued clinical guidelines endorsing the use of digoxin for patients with systolic dysfunction.
The current study was conducted among 2,891 adults within Kaiser Permanente in Northern California who had newly diagnosed systolic heart failure between 2006 and 2008 and no prior digoxin use. Eighteen percent of the participants initiated digoxin during the study period.
Researchers followed the patients through December 31, 2010, to evaluate the effectiveness and safety of digoxin therapy. They found that digoxin use was associated with higher mortality but no significant difference in the risk of heart failure hospitalization.
There were a total of 801 deaths (737 off digoxin and 64 on digoxin). After adjustment for potential confounders, digoxin use was associated with a 72 percent higher relative rate of death.
There were 1,723 hospitalizations for heart failure overall (1,596 off digoxin, 127 on digoxin). However, after adjustment for potential confounders, digoxin use was not significantly associated with hospitalization for heart failure.
"Our community-based study population is more likely to represent patients with systolic heart failure in the modern era with regard to pathogenesis and treatment patterns," Dr. Go said. "Therefore, our results may more accurately represent the outcomes expected with digoxin for patients with systolic heart failure in typical present-day practices. As with all medication, treatment, or therapy plans, care decisions should always be made by physicians and their patients working together, with the patient's particular care needs and goals in mind."
Explore further: Study finds common drug increases deaths in atrial fibrillation patients
Medical Xpress on facebook
Related Stories
Study finds common drug increases deaths in atrial fibrillation patients
Nov 27, 2012
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of ...
Digoxin reduces hospital admissions in older patients with chronic heart failure
Mar 12, 2013
Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented today ...
Popular heart drug may be unsafe for some kidney patients
Jun 24, 2010
For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American So ...
New study finds digoxin safe despite recent reports
Apr 16, 2013
A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation (AF), the opposite of results just published by another group in the same journa ...
Ancient heart drug activates body's own protective mechanisms in blood vessels
Jun 14, 2012
An ancient heart drug that's inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.
Recommended for you
Groundbreaking procedure using novel 'paper-clip' style device to treat high blood pressure
4 hours ago
Researchers at the University of Leicester and Glenfield Hospital have successfully used a novel "paper-clip" sized vascular coupling device to tackle resistant high blood pressure.
Increased QRS duration on ECG tied to cardiovascular mortality
23 hours ago
(HealthDay)—Increased QRS duration on electrocardiogram (ECG) is an independent predictor of cardiovascular mortality, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.
Researchers envision switching a heart beat on and off with light
Sep 19, 2013
With a few flicks of a light switch—on-off-on-off—Stanford University's Oscar Abilez is one step closer to changing the lives of millions.
National registry report shows increase in radial stenting, other CV trends
Sep 18, 2013
Cardiologists are increasingly accessing coronary arteries by way of the wrist rather than the groin to insert life-saving stents into patients with blocked arteries, according to the first broad report of the American College ...
UCLA doctors successfully 'vacuum' two-foot blood clot out of patient's heart
Sep 18, 2013
Todd Dunlap, 62, arrived at Ronald Reagan UCLA Medical Center's emergency room on Aug. 8 suffering from shortness of breath, fatigue and extreme cold. When a CT scan revealed a 24-inch clot stretching from his legs into his ...
Different hormone therapy formulations may pose different risks for heart attack and stroke
Sep 18, 2013
Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment